RECURRENT GLIOBLASTOMA

This early-stage trial tests a new type of CAR T-cell therapy designed to target a protein called MMP2 found on glioblastoma cells. The treatment uses a scorpion toxin fragment (chlorotoxin) to help the immune cells find and attack the tumor. Nineteen patients with recurrent or p…

This early-phase trial is testing the immunotherapy drug nivolumab in children and young adults whose high-grade glioma has come back or is getting worse. Participants receive the drug before and after surgery to remove as much of the tumor as possible. The main goals are to chec…

This study tests whether a combination of two immunotherapy drugs (relatlimab and nivolumab) is safer and more effective than standard chemotherapy (lomustine) for people whose glioblastoma (a type of aggressive brain cancer) has returned after initial treatment. About 184 partic…

This early-phase trial tests whether a special type of immune cell (CAR T cell) that targets a protein found on glioblastoma cells can be safely given along with two immunotherapy drugs (nivolumab and ipilimumab). The study involves 20 adults with recurrent or treatment-resistant…

This early-phase trial tests whether adding the drug mycophenolate mofetil (MMF) to standard radiation therapy is safe for people with glioblastoma, an aggressive brain cancer. About 68 participants with newly diagnosed or recurrent glioblastoma will receive different doses of MM…

This early-phase trial tests a new approach for people with aggressive brain tumors that have come back. Doctors place genetically modified neural stem cells directly into the tumor to make it more sensitive to the chemotherapy drug irinotecan. The study involves 18 participants …

This phase 2 trial is testing an oral drug called ACT001 in 12 adults whose glioblastoma has returned after standard treatment. The study focuses on patients whose tumors have a specific genetic signature (STAT3-high). Researchers will check if the drug can shrink or stabilize th…

This trial tests an implantable ultrasound device that temporarily opens the blood-brain barrier, allowing chemotherapy to reach brain tumors. It includes 57 adults with recurrent glioblastoma who have already tried 1-2 treatments. The goal is to find a safe dose and see if this …

This study tests a combination of two drugs (tocilizumab and atezolizumab) plus targeted radiation in people whose glioblastoma brain tumor has returned. The goal is to make the tumor more responsive to the body's immune system. About 59 adults will take part to find the best dos…

This early-phase study tests a new drug (BGB-290) combined with chemotherapy (temozolomide) in teens and young adults with a type of brain tumor called glioma that has an IDH mutation. The goal is to find the safest dose and see how well the combination works for both newly diagn…

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This early-phase trial tests adding mycophenolate mofetil, a drug usually used to prevent organ rejection, to standard chemotherapy and radiation for glioblastoma. The goal is to find a safe dose and see if the combination can make tumor cells more sensitive to treatment. About 6…

This phase 2 trial tests a combination of the drug niraparib and a device that delivers electric fields (Tumor-Treating Fields) in 30 people with recurrent glioblastoma, an aggressive brain cancer. The goal is to see if the combo can control the tumor, shrink it, or keep it stabl…

This early trial tests two oral drugs, defactinib and VS-6766, in 14 people with glioblastoma. The goal is to see how much drug reaches the brain tumor and check for side effects. Both drugs block different growth pathways that help glioblastoma cells grow. This study only looks …

This was a very early phase 1 trial that planned to test a personalized immune cell therapy for people with recurrent glioblastoma, an aggressive brain cancer. The treatment involved taking a patient's own T cells, activating them in a lab to target cancer stem cells, and giving …

This early-stage trial tests a personalized immunotherapy for people with malignant glioma that has returned or not responded to standard treatment. The patient's own T-cells are collected, genetically modified in a lab to recognize and attack glioma cells, and then infused back …

This study tests whether a special MRI scan, called DSC-MRI, can measure blood flow changes in brain tumors to predict if the drug bevacizumab is working early in treatment. Researchers will scan 146 patients with recurrent glioblastoma before and two weeks after starting the dru…